Active, intact FGF23, a key component in phosphate regulation, increases after treatment with certain IV iron preparations, leading to increased urinary excretion of phosphate and, thus, hypophosphatemia [6, 29, 30]. The gene discussed is FGF23; the disease is hypophosphatemia.